Skip to content

Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia

Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01670825
Enrollment
81
Registered
2012-08-22
Start date
2012-08-31
Completion date
2015-02-28
Last updated
2017-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Occipital Neuralgia

Keywords

Occipital neuralgia, corticosteroid injection, pulsed radiofrequency

Brief summary

The aim of this study is to determine whether pulsed radiofrequency or steroids are better for occipital neuralgia. Seventy-six patients with ON or migraine with tenderness over the occipital nerve who respond to occipital nerve blocks (hereafter included under the broad category ON) will be randomized in a 1:1 ratio to receive either corticosteroid and local anesthetic injections (n=38) or local anesthetic and PRF of the occipital nerve(s) (n=38) for occipital neuralgia. Both patients and the treating & evaluating physicians will be blinded. The first follow-up visit will be at 6 weeks. Patients who obtain significant pain relief will remain in the study. Those patients who fail to obtain any benefit will exit the study and be allowed to crossover to the other treatments or receive alternative care. The second follow-up will be at 3 months and the final follow-up will be at 6-months post-procedure.

Detailed description

Up to 76 patients referred to one of the participating pain clinic with occipital neuralgia, or migraines with occipital nerve tenderness (dual diagnoses) will be randomized in a 1:1 ratio by a computer generated randomization table to receive one of two treatments. Treatments will be randomized at each institution. Within each group, those patients with plain occipital neuralgia, and those with occipital neuralgia with migraines, will be sub-randomized in the same 1:1 ratio. Diagnosis of ON will be made by low-volume (\< 3 mL bupivacaine per nerve). Our criterion for a positive response will be \> 50% pain relief lasting at least 3 hours. Those individuals who have symptoms in the distribution of both the greater and lesser occipital nerves will receive treatment of both nerves. The greater occipital nerve is more frequently affected than the lesser nerve. Half (n=38) of the patients will be allocated to receive local anesthetic & corticosteroid injections at each nerve (group I), with an equal number allocated to receive local anesthetic & PRF at each (group II). In those patients who request sedation, an intravenous will be inserted and light sedation administered with low doses of midazolam and fentanyl, in accordance with our standard clinic practice. Treatment in all patients will be accomplished using 20-gauge radiofrequency needles with 10 mm active tips. Prior to treating, electrical stimulation will be performed to ensure ample proximity to the targeted nerve(s), with our target threshold being concordant stimulation at \< 0.3 volts at each site. Once proper needle position is ensured, those in group I will receive an injection at each nerve containing 30 mg of depomethylprednisolone mixed with 2 mL of a 50:50 mixture of 2% lidocaine and 0.5% bupivacaine (2.75 mL). Anywhere between 1 and 4 nerves can be injected, with 4 nerves being targeted if a patient had bilateral lesser and greater occipital nerve involvement. This will be followed by 3 cycles of sham PRF at 120 s per cycle, with slight (approximately 30o electrode adjustments between cycles. For sham PRF, no electrical field or heat is generated (i.e. the machine is not set to any radiofrequency cycle after stimulation), but the cycle times (120 s per cycle) are adhered to (i.e. we will wait a total of 6, 2 per cycle). Those patients in group II will receive injections at each nerve containing 2.75 mL of a solution with 2 mL of 50:50 2% lidocaine and 0.5% bupivacaine + 0.75 mL saline (2.75 mL), followed by 3 cycles of PRF using the following standard settings: voltage output 40-60 V; 2 Hz frequency; 20 ms pulses in a 1-second cycle, 120 second duration per cycle; impedance range between 150 and 400 Ohms; and 42o C plateau temperature. No patient will be prescribed additional medications or therapy between their procedure and first follow-up. However, they will be allowed to remain on their current, stable analgesic regimen. Rescue medications will consist of tramadol 50 mg 1 to 2 tablets every 6 hours PRN (up to 8/d) and/or acetaminophen or a non-steroidal anti-inflammatory drug such as ibuprofen, diclofenac or ketorolac on an as needed basis. Follow-ups will be performed by a physician blinded to treatment allocation. A preliminary follow-up will be performed at weeks. The first full follow-up visit will be scheduled 6-weeks from the start of treatment. A positive outcome will be defined as a \> 50% decrease in headache coupled with a positive satisfaction rating (\> 3 on a 0-5 scale). Subjects who obtain a positive outcome at their initial 6-week follow-up visit will remain in the study and return for their 3-month follow-up visit. Those with a negative outcome will exit the study per protocol to receive standard care. Subjects who obtain a positive outcome at 1-month but experience a recurrence before their 3-month follow-up visit will also exit the study per protocol, with their final outcome measures recorded before they receive standard care. Those who obtain a positive outcome at 3-months will remain in the study for their final 6-month follow-up, while those who obtain a negative outcome will exit the study. Unblinding for both patients and the treating physician will be after the patient exits the study or after their final follow-up visit for those with continued benefit.

Interventions

PROCEDUREPulsed radiofrequency

Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve

DRUGCorticosteroid injection

Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve

DRUGLocal anethestic injection

Sponsors

United States Naval Medical Center, San Diego
CollaboratorFED
Landstuhl Regional Medical Center
CollaboratorFED
Madigan Army Medical Center
CollaboratorFED
United States Naval Medical Center, Portsmouth
CollaboratorFED
Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

1. Age greater or equal to 18 years 2. Occipital neuralgia diagnosed based on history & physical exam and diagnostic local anesthetic blocks, or migraine with occipital nerve(s) tenderness that responds to diagnostic blocks. a. Greater or equal to 50% relief based on diagnostic local anesthetic block of the greater and/ or lesser occipital nerves that lasts for at least 90 minutes with lidocaine or 3 hours with bupivacaine or ropivacaine 20 3. Baseline Numerical Rating Scale average pain score \> 4/10 4. Frequency of greater or equal to 4/10 pain for at least 10 days per month

Exclusion criteria

1. Untreated coagulopathy 2. Automatic implantable cardiac defibrillator or pacemaker that cannot be temporarily disabled for medical reasons 3. Previous pulsed radiofrequency 4. Other sources of headache, such as tension-type headache, cervicogenic headache, migraine headache without occipital neuralgia, and other causes (e.g. tumors, congenital abnormalities etc.). Those that can be confused with ON must be excluded based on history and exam (e.g. cervicogenic headaches), symptoms (tension-type headache), response to blocks (all of the above); and lab work (temporal arteritis, which would be confirmed by biopsy after an elevated erythrocyte sedimentation rate). 5. Serious medical or uncontrolled or severe psychiatric -

Design outcomes

Primary

MeasureTime frameDescription
Change in Overall Worst Headache Pain 6 Months After the Start of TreatmentFrom baseline to 6 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Average Occipital Pain 6 Weeks After the Start of TreatmentFrom baseline to 6 weeks after the start of treatmentThe change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Worst Occipital Pain 6 Weeks After the Start of TreatmentFrom baseline to 6 weeks after the start of treatmentThe change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Average Occipital Pain 6 Months After the Start of TreatmentFrom baseline to 6 months after the start of treatmentThe change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Worst Occipital Pain 6 Months After the Start of TreatmentFrom baseline to 6 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Average Occipital Pain 3 Months After the Start of TreatmentFrom baseline to 3 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Worst Occipital Pain 3 Months After the Start of TreatmentFrom baseline to 3 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Average Occipital Pain 2 Weeks After the Start of TreatmentFrom baseline to 2 weeks after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Worst Occipital Pain 2 Weeks After the Start of TreatmentFrom baseline to 2 weeks after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Average Headache Pain 2 Weeks After the Start of TreatmentFrom baseline to 2 weeks after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Worst Headache Pain 2 Weeks After the Start of TreatmentFrom baseline to 2 weeks after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Average Headache Pain 6 Weeks After the Start of TreatmentFrom baseline to 6 weeks after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Worst Overall Headache Pain 6 Weeks After the Start of TreatmentFrom baseline to 6 weeks after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Average Headache Pain 3 Months After the Start of TreatmentFrom baseline to 3 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Worst Headache Pain 3 Months After the Start of TreatmentFrom baseline to 3 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.
Change in Overall Average Headache Pain 6 Months After the Start of TreatmentFrom baseline to 6 months after the start of treatmentThis outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Secondary

MeasureTime frameDescription
Change in the Presence of Insomnia 3 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.From baseline to 3 months after the start of treatmentThis outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia.
Change in the Presence of Insomnia 6 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.From baseline to 6 months after the start of treatmentThis outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia.
Change in the Severity of Depression 6 Weeks After the Start of Treatment Measured Using the Beck's Depression InventoryFrom baseline to 6 weeks after the start of treatmentThis outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression.
Change in the Severity of Depression 3 Months After the Start of Treatment Measured Using the Beck's Depression InventoryFrom baseline to 3 months after the start of treatmentThis outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression.
Change in the Severity of Depression 6 Months After the Start of Treatment Measured Using the Beck's Depression InventoryFrom baseline to 6 months after the start of treatmentThis outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression.
Severe Headache Frequency for Migraine Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headaches in the Past Week.From baseline to 6 weeks after the start of treatmentThis outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.
Severe Headache Frequency for Occipital Neuralgia Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study VisitFrom baseline to 6 weeks after the start of treatmentThis outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.
Severe Headache Frequency for Migraine Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study VisitFrom baseline to 3 months after the start of treatmentThis outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.
Severe Headache Frequency for Occipital Neuralgia Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit3 monthsThis outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.
Severe Headache Frequency for Migraine Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study VisitFrom baseline to 6 months after the start of treatmentThis outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.
Severe Headache Frequency for Occipital Neuralgia Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study VisitFrom baseline to 6 months after the start of treatmentThis outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.
Disability Due to Headaches 6 Weeks After the Start of Treatment Measured Using the Headache Impact ScaleFrom baseline to 6 weeks after the start of treatmentThis outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life.
Disability Due to Headaches 3 Months After the Start of Treatment Measured Using the Headache Impact ScaleFrom baseline to 3 months after the start of treatmentThis outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life.
Disability Due to Headaches 6 Months After the Start of Treatment Measured Using the Headache Impact ScaleFrom baseline to 6 months after the start of treatmentThis outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life.
Change in the Presence of Insomnia 6 Weeks After the Start of Treatment Measured Using the Athens Insomnia Scale.From baseline to 6 weeks after the start of treatmentThis outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia.

Countries

United States

Participant flow

Participants by arm

ArmCount
Pulsed Radiofrequency + Local Anesthetic Injection
Local anesthetic injection plus pulsed radiofrequency over each affected occipital nerve Pulsed radiofrequency: Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
42
Corticosteroid Injection + Sham Pulsed Radiofrequency
Injection with corticosteroid and local anesthetic over the occipital nerve(s)plus sham pulsed radiofrequency Corticosteroid injection: Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
39
Total81

Baseline characteristics

CharacteristicPulsed Radiofrequency + Local Anesthetic InjectionCorticosteroid Injection + Sham Pulsed RadiofrequencyTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
42 Participants39 Participants81 Participants
Age, Continuous41.67 years
STANDARD_DEVIATION 10.72
41.08 years
STANDARD_DEVIATION 13.61
41.37 years
STANDARD_DEVIATION 12.16
Gender
Female
20 Participants18 Participants38 Participants
Gender
Male
22 Participants21 Participants43 Participants
Region of Enrollment
Germany
1 participants1 participants2 participants
Region of Enrollment
United States
41 participants38 participants79 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 420 / 39
serious
Total, serious adverse events
3 / 426 / 39

Outcome results

Primary

Change in Average Occipital Pain 2 Weeks After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 2 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Average Occipital Pain 2 Weeks After the Start of Treatment2.495 units on a scaleStandard Deviation 2.094
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Average Occipital Pain 2 Weeks After the Start of Treatment3.694 units on a scaleStandard Deviation 2.221
Primary

Change in Average Occipital Pain 3 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Average Occipital Pain 3 Months After the Start of Treatment3.791 units on a scaleStandard Deviation 2.573
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Average Occipital Pain 3 Months After the Start of Treatment4.441 units on a scaleStandard Deviation 2.237
Primary

Change in Average Occipital Pain 6 Months After the Start of Treatment

The change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Average Occipital Pain 6 Months After the Start of Treatment4.312 units on a scaleStandard Deviation 2.232
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Average Occipital Pain 6 Months After the Start of Treatment4.765 units on a scaleStandard Deviation 1.998
Primary

Change in Average Occipital Pain 6 Weeks After the Start of Treatment

The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Average Occipital Pain 6 Weeks After the Start of Treatment3.068 units on a scaleStandard Deviation 2.431
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Average Occipital Pain 6 Weeks After the Start of Treatment3.738 units on a scaleStandard Deviation 2.415
Primary

Change in Overall Average Headache Pain 2 Weeks After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 2 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Average Headache Pain 2 Weeks After the Start of Treatment3.392 units on a scaleStandard Deviation 2.106
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Average Headache Pain 2 Weeks After the Start of Treatment4.220 units on a scaleStandard Deviation 2.496
Primary

Change in Overall Average Headache Pain 3 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Average Headache Pain 3 Months After the Start of Treatment4.000 units on a scaleStandard Deviation 2.87
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Average Headache Pain 3 Months After the Start of Treatment4.694 units on a scaleStandard Deviation 2.48
Primary

Change in Overall Average Headache Pain 6 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Average Headache Pain 6 Months After the Start of Treatment6.761 units on a scaleStandard Deviation 3.096
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Average Headache Pain 6 Months After the Start of Treatment7.556 units on a scaleStandard Deviation 2.623
Primary

Change in Overall Average Headache Pain 6 Weeks After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Average Headache Pain 6 Weeks After the Start of Treatment3.678 units on a scaleStandard Deviation 2.448
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Average Headache Pain 6 Weeks After the Start of Treatment4.410 units on a scaleStandard Deviation 2.544
Primary

Change in Overall Worst Headache Pain 2 Weeks After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 2 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Worst Headache Pain 2 Weeks After the Start of Treatment5.540 units on a scaleStandard Deviation 2.669
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Worst Headache Pain 2 Weeks After the Start of Treatment6.650 units on a scaleStandard Deviation 2.744
Primary

Change in Overall Worst Headache Pain 3 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Worst Headache Pain 3 Months After the Start of Treatment6.522 units on a scaleStandard Deviation 3.232
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Worst Headache Pain 3 Months After the Start of Treatment7.417 units on a scaleStandard Deviation 2.952
Primary

Change in Overall Worst Headache Pain 6 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Worst Headache Pain 6 Months After the Start of Treatment6.761 units on a scaleStandard Deviation 3.096
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Worst Headache Pain 6 Months After the Start of Treatment7.556 units on a scaleStandard Deviation 2.623
Primary

Change in Overall Worst Overall Headache Pain 6 Weeks After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Overall Worst Overall Headache Pain 6 Weeks After the Start of Treatment6.583 units on a scaleStandard Deviation 3.202
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Overall Worst Overall Headache Pain 6 Weeks After the Start of Treatment6.825 units on a scaleStandard Deviation 3.109
Primary

Change in Worst Occipital Pain 2 Weeks After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 2 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Worst Occipital Pain 2 Weeks After the Start of Treatment4.726 units on a scaleStandard Deviation 2.528
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Worst Occipital Pain 2 Weeks After the Start of Treatment5.846 units on a scaleStandard Deviation 2.618
Primary

Change in Worst Occipital Pain 3 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Worst Occipital Pain 3 Months After the Start of Treatment5.850 units on a scaleStandard Deviation 3.292
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Worst Occipital Pain 3 Months After the Start of Treatment7.149 units on a scaleStandard Deviation 2.967
Primary

Change in Worst Occipital Pain 6 Months After the Start of Treatment

This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Worst Occipital Pain 6 Months After the Start of Treatment6.705 units on a scaleStandard Deviation 2.892
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Worst Occipital Pain 6 Months After the Start of Treatment7.541 units on a scaleStandard Deviation 2.416
Primary

Change in Worst Occipital Pain 6 Weeks After the Start of Treatment

The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in Worst Occipital Pain 6 Weeks After the Start of Treatment5.354 units on a scaleStandard Deviation 3.165
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in Worst Occipital Pain 6 Weeks After the Start of Treatment6.064 units on a scaleStandard Deviation 3.226
Secondary

Change in the Presence of Insomnia 3 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.

This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in the Presence of Insomnia 3 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.9.539 units on a scaleStandard Deviation 6.043
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in the Presence of Insomnia 3 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.9.069 units on a scaleStandard Deviation 5.955
Secondary

Change in the Presence of Insomnia 6 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.

This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in the Presence of Insomnia 6 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.9.256 units on a scaleStandard Deviation 6.21
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in the Presence of Insomnia 6 Months After the Start of Treatment Measured Using the Athens Insomnia Scale.9.431 units on a scaleStandard Deviation 5.765
Secondary

Change in the Presence of Insomnia 6 Weeks After the Start of Treatment Measured Using the Athens Insomnia Scale.

This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in the Presence of Insomnia 6 Weeks After the Start of Treatment Measured Using the Athens Insomnia Scale.10.025 units on a scaleStandard Deviation 5.972
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in the Presence of Insomnia 6 Weeks After the Start of Treatment Measured Using the Athens Insomnia Scale.8.132 units on a scaleStandard Deviation 5.297
Secondary

Change in the Severity of Depression 3 Months After the Start of Treatment Measured Using the Beck's Depression Inventory

This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in the Severity of Depression 3 Months After the Start of Treatment Measured Using the Beck's Depression Inventory11.333 units on a scaleStandard Deviation 10.207
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in the Severity of Depression 3 Months After the Start of Treatment Measured Using the Beck's Depression Inventory11.972 units on a scaleStandard Deviation 10.287
Secondary

Change in the Severity of Depression 6 Months After the Start of Treatment Measured Using the Beck's Depression Inventory

This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in the Severity of Depression 6 Months After the Start of Treatment Measured Using the Beck's Depression Inventory12.590 units on a scaleStandard Deviation 10.684
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in the Severity of Depression 6 Months After the Start of Treatment Measured Using the Beck's Depression Inventory12.250 units on a scaleStandard Deviation 10.103
Secondary

Change in the Severity of Depression 6 Weeks After the Start of Treatment Measured Using the Beck's Depression Inventory

This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionChange in the Severity of Depression 6 Weeks After the Start of Treatment Measured Using the Beck's Depression Inventory12.775 units on a scaleStandard Deviation 11.079
Corticosteroid Injection + Sham Pulsed RadiofrequencyChange in the Severity of Depression 6 Weeks After the Start of Treatment Measured Using the Beck's Depression Inventory10.842 units on a scaleStandard Deviation 9.945
Secondary

Disability Due to Headaches 3 Months After the Start of Treatment Measured Using the Headache Impact Scale

This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionDisability Due to Headaches 3 Months After the Start of Treatment Measured Using the Headache Impact Scale59.718 units on a scaleStandard Deviation 9.761
Corticosteroid Injection + Sham Pulsed RadiofrequencyDisability Due to Headaches 3 Months After the Start of Treatment Measured Using the Headache Impact Scale60.556 units on a scaleStandard Deviation 10.814
Secondary

Disability Due to Headaches 6 Months After the Start of Treatment Measured Using the Headache Impact Scale

This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionDisability Due to Headaches 6 Months After the Start of Treatment Measured Using the Headache Impact Scale59.641 units on a scaleStandard Deviation 10.251
Corticosteroid Injection + Sham Pulsed RadiofrequencyDisability Due to Headaches 6 Months After the Start of Treatment Measured Using the Headache Impact Scale61.389 units on a scaleStandard Deviation 8.8
Secondary

Disability Due to Headaches 6 Weeks After the Start of Treatment Measured Using the Headache Impact Scale

This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionDisability Due to Headaches 6 Weeks After the Start of Treatment Measured Using the Headache Impact Scale60.087 units on a scaleStandard Deviation 7.972
Corticosteroid Injection + Sham Pulsed RadiofrequencyDisability Due to Headaches 6 Weeks After the Start of Treatment Measured Using the Headache Impact Scale59.553 units on a scaleStandard Deviation 9.093
Secondary

Severe Headache Frequency for Migraine Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit

This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.

Time frame: From baseline to 3 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionSevere Headache Frequency for Migraine Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit2.087 daysStandard Deviation 2.109
Corticosteroid Injection + Sham Pulsed RadiofrequencySevere Headache Frequency for Migraine Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit2.263 daysStandard Deviation 2.232
Secondary

Severe Headache Frequency for Migraine Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit

This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionSevere Headache Frequency for Migraine Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit2.044 daysStandard Deviation 2.099
Corticosteroid Injection + Sham Pulsed RadiofrequencySevere Headache Frequency for Migraine Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit2.368 daysStandard Deviation 2.409
Secondary

Severe Headache Frequency for Migraine Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headaches in the Past Week.

This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionSevere Headache Frequency for Migraine Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headaches in the Past Week.1.708 daysStandard Deviation 1.958
Corticosteroid Injection + Sham Pulsed RadiofrequencySevere Headache Frequency for Migraine Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headaches in the Past Week.1.810 daysStandard Deviation 2.421
Secondary

Severe Headache Frequency for Occipital Neuralgia Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit

This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.

Time frame: 3 months

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionSevere Headache Frequency for Occipital Neuralgia Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit1.846 daysStandard Deviation 2.335
Corticosteroid Injection + Sham Pulsed RadiofrequencySevere Headache Frequency for Occipital Neuralgia Headaches 3 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit1.919 daysStandard Deviation 2.046
Secondary

Severe Headache Frequency for Occipital Neuralgia Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit

This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.

Time frame: From baseline to 6 months after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionSevere Headache Frequency for Occipital Neuralgia Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit2.128 daysStandard Deviation 2.308
Corticosteroid Injection + Sham Pulsed RadiofrequencySevere Headache Frequency for Occipital Neuralgia Headaches 6 Months After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit2.162 daysStandard Deviation 2.154
Secondary

Severe Headache Frequency for Occipital Neuralgia Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit

This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale.

Time frame: From baseline to 6 weeks after the start of treatment

ArmMeasureValue (MEAN)Dispersion
Pulsed Radiofrequency + Local Anesthetic InjectionSevere Headache Frequency for Occipital Neuralgia Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit1.436 daysStandard Deviation 2.237
Corticosteroid Injection + Sham Pulsed RadiofrequencySevere Headache Frequency for Occipital Neuralgia Headaches 6 Weeks After the Start of Treatment Measured Asking the Number of Severe Headache Days 1 Week Prior to Study Visit1.436 daysStandard Deviation 2.087

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026